Abstract：
:Preliminary results of a phase II study of gemcitabine plus trastuzumab in previously treated (up to 3 previous regimens) metastatic breast cancer patients are presented. Patients had histologically confirmed metastatic breast cancer, with 2+ or 3+ tumor HER2 expression. Treatment consisted of gemcitabine 1200 mg/m2 over 30 minutes intravenously on days 1 and 8 every 21 days, and trastuzumab 4 mg/kg over 90 minutes, followed by 2 mg/kg infused over 30 minutes weekly. Treatment was continued until disease progression or unacceptable toxicity occurred. Preliminary results are available on the first 38 patients enrolled. Median patient age was 53 years, 53% had estrogen receptor/progesterone receptor-positive disease, and HER2 staining was 2+ in 39% and 3+ in 61% of patients. There was a median of 3 previously administered (including adjuvant) chemotherapy regimens, and a median of 4.5 treatment cycles per patient has been administered so far. Twelve patients (32%) have had an objective partial response, with a median response duration of 8.6 months. Median time to disease progression is 6.7 months to date, with a median overall survival of 10.2 months. No unexpected toxicities or grade 4 nonhematologic toxicities have been observed; 2 patients developed grade 4 neutropenia and 1 patient had febrile neutropenia. Thus, gemcitabine/ trastuzumab resulted in an encouraging 32% response rate, given the heavily pretreated patient population. Tolerability was good overall, with no unexpected side effects observed.
journal_name
Clin Breast Cancerjournal_title
Clinical breast cancerauthors
O'Shaughnessy J,Vukelja SJ,Marsland T,Kimmel G,Ratnam S,Pippen Jdoi
10.3816/cbc.2002.s.004keywords:
subject
Has Abstractpub_date
2002-05-01 00:00:00pages
17-20eissn
1526-8209issn
1938-0666pii
S1526-8209(11)70281-6journal_volume
3 Suppl 1pub_type
临床试验,杂志文章abstract：BACKGROUND:Several studies conducted in developed countries introduced diet and physical inactivity as major risk factors for several types of cancers. However, the impact of diet and physical inactivity on the risk of breast cancer (BC) is understudied, and the limited findings are controversial. In addition, no or li...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2018.10.011
更新日期：2019-02-01 00:00:00
abstract：:Chemotherapeutic agents that disrupt the assembly or disassembly of microtubules, including paclitaxel and docetaxel, are among the most commonly prescribed anticancer therapies. However, the utility of taxane-based therapy is limited principally by problems with formulation, slow administration, cumulative neurotoxic...
journal_title：Clinical breast cancer
pub_type： 杂志文章,评审
doi：10.3816/cbc.2008.s.001
更新日期：2008-03-01 00:00:00
abstract：:Breast cancer patients who present with nodal metastasis receive neoadjuvant chemotherapy (NAC) with increasing frequency and can have complete pathologic response after treatment. In this clinical scenario, sentinel node mapping and biopsy are gaining acceptance instead of axillary dissection to avoid morbidity. Biop...
journal_title：Clinical breast cancer
pub_type： 杂志文章,评审
doi：10.1016/j.clbc.2018.01.004
更新日期：2018-08-01 00:00:00
abstract：BACKGROUND:The American Joint Committee on Cancer (AJCC) staging system is the reference standard for describing the extent of neoplastic disease on the basis of the size of primary tumor (T), and the presence of regional lymph node (N) involvement and distant metastasis (M). Multiple foci of invasive breast carcinoma ...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2020.11.018
更新日期：2020-12-05 00:00:00
abstract：BACKGROUND:Based on preclinical studies and a phase I trial of the combination of bortezomib and pegylated liposomal doxorubicin (PLD), which both showed activity in breast cancer, we conducted a phase II study of this regimen in patients with metastatic breast cancer. PATIENTS AND METHODS:Patients received bortezomib...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.3816/CBC.2010.n.061
更新日期：2010-12-01 00:00:00
abstract：BACKGROUND:Postmenopausal women with osteoporosis had a 66% relative risk reduction for invasive breast cancer over 8 years of raloxifene therapy in the randomized, placebo-controlled 4-year MORE (Multiple Outcomes of Raloxifene Evaluation) trial and the CORE (Continuing Outcomes Relevant to Evista) trial, a 4-year fol...
journal_title：Clinical breast cancer
pub_type： 杂志文章,多中心研究,随机对照试验
doi：10.3816/CBC.2009.n.008
更新日期：2009-02-01 00:00:00
abstract：UNLABELLED:This is a retrospective study on 40 breast cancer patients, of which 20 have bone metastases, 10 have visceral metastases, and 10 have no evidence of disease, aimed at evaluating the role of CXCR4 and the RANK/RANKL/OPG system to predict bone metastases. CXCR4 expression, alone or in combination with RANK, i...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2011.05.001
更新日期：2011-12-01 00:00:00
abstract：BACKGROUND:Triple-negative breast cancer (TNBC) is an aggressive disease without established targeted treatment options for patients with metastatic disease. This study was undertaken to evaluate potentially actionable biomarkers in a large cohort of TNBC and compare them with non-TNBCs. MATERIALS AND METHODS:We evalu...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2015.04.008
更新日期：2015-12-01 00:00:00
abstract：INTRODUCTION:Axillary lymph node dissection (ALND) is currently the recommended procedure in patients with tumor-positive sentinel lymph node biopsy (SLNB). A significant proportion of patients with positive SLNs will not have any additional metastases in nonsentinel lymph nodes (NSLNs). Predictive nomograms could iden...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2014.02.006
更新日期：2014-08-01 00:00:00
abstract：:Breast cancer is the second leading cause of cancer death in women, affecting 1.7 million patients every year worldwide. As a result of its heterogeneous nature, the genetic profile and associated clinical feature varies greatly among different breast cancer subtypes. With the advancement of molecular biology, our und...
journal_title：Clinical breast cancer
pub_type： 杂志文章,评审
doi：10.1016/j.clbc.2016.05.012
更新日期：2016-10-01 00:00:00
abstract：PURPOSE:The purpose of this study is to determine the response, tolerability, and long-term outcome of a neoadjuvant platinum-containing regimen for locally advanced breast cancer (LABC) and to search for a correlation between pathologic complete response (pCR) and predefined biomarkers in this cohort. PATIENTS AND ME...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.3816/CBC.2009.n.027
更新日期：2009-08-01 00:00:00
abstract：BACKGROUND:Single-frequency bioelectrical impedance (BI) has been used to measure extracellular fluid in the upper limbs. The purpose of the study was to evaluate BI's ability to detect and monitor upper limb changes in based upon the extent of various treatments and to assess its practicality. METHODS:Patients with n...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2012.01.004
更新日期：2012-04-01 00:00:00
abstract：:Pathologic complete remission after neoadjuvant chemotherapy has a role in guiding the management of breast cancer. The present meta-analysis examined the accuracy of contrast-enhanced magnetic resonance imaging (CE-MRI) and diffusion-weighted magnetic resonance imaging (DW-MRI) in detecting the response to neoadjuvan...
journal_title：Clinical breast cancer
pub_type： 杂志文章,评审
doi：10.1016/j.clbc.2016.12.010
更新日期：2017-07-01 00:00:00
abstract：:Breast cancer is one of the most frequently diagnosed malignancy among adolescent and young adult (AYA) women, accounting for approximately 14% of all AYA cancer diagnoses and 7% of all breast cancer. Breast cancer in AYA women is believed to represent a more biologically aggressive disease, but aside from commonly kn...
journal_title：Clinical breast cancer
pub_type： 杂志文章,评审
doi：10.1016/j.clbc.2014.06.002
更新日期：2014-12-01 00:00:00
abstract：:The potential for cardiac toxicity in association with targeted biologic agents was first observed with trastuzumab, a monoclonal antibody that targets the ErbB2/HER2 receptor. In the pivotal trial of trastuzumab in ErbB2-positive metastatic cancer, an increased incidence of serious cardiac events was observed, partic...
journal_title：Clinical breast cancer
pub_type： 杂志文章,评审
doi：10.3816/cbc.2008.s.007
更新日期：2008-03-01 00:00:00
abstract：BACKGROUND:Causes of racial disparities in breast cancer survival remain unclear. This study assesses overall survival (OS) after diagnosis between black and white women and examines factors that might correlate with this disparity. PATIENTS AND METHODS:Data were obtained from the Medical College of Georgia Tumor Regi...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.3816/CBC.2010.n.008
更新日期：2010-02-01 00:00:00
abstract：BACKGROUND:The [18F]-fluorodeoxyglucose positron emission tomography (FDG-PET) cancer screening program is defined as cancer screening for asymptomatic subjects using FDG-PET/computed tomography with or without combination of other screening tests. The aim of this study was to analyze the detection rate and effectivene...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2014.09.008
更新日期：2015-04-01 00:00:00
abstract：INTRODUCTION:The purpose of the study was to determine predictors of recurrence for patients treated with neoadjuvant chemotherapy (NAC) and mastectomy according to the use of postmastectomy radiation therapy (PMRT). PATIENTS AND METHODS:An analysis of 161 clinically staged T1 to T3/N0 to N3 patients treated with NAC ...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2014.09.012
更新日期：2015-04-01 00:00:00
abstract：PURPOSE:There is no consensus regarding treatment for patients with breast cancer and isolated sternal involvement. Though classified as AJCC stage IV, this group of patients may have prolonged distant disease free survival. PATIENTS AND METHODS:Retrospective case series of 8 patients with isolated sternal recurrence....
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2011.03.017
更新日期：2011-06-01 00:00:00
abstract：BACKGROUND:Two large randomized trials, CALGB 9343 and PRIME II, support omission of radiotherapy after breast conserving surgery (BCS) in elderly women with favorable-risk early stage breast cancer intending to take endocrine therapy. However, patients with grade 3 histology were underrepresented on these trials. We h...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2020.05.007
更新日期：2020-12-01 00:00:00
abstract：:Fulvestrant, an estrogen receptor antagonist that downregulates the estrogen receptor but has no known agonist effects, has been evaluated in 2 randomized trials involving postmenopausal women with hormone receptor-positive, progressive advanced-stage breast cancer after disease progression with antiestrogen therapy. ...
journal_title：Clinical breast cancer
pub_type： 杂志文章,评审
doi：10.3816/cbc.2005.s.009
更新日期：2005-04-01 00:00:00
abstract：BACKGROUND:Spontaneous rib fractures (SRFs) are defined as fractures without apparent blunt force trauma. This study evaluated the incidence and risk factors of SRFs after treatment of patients with breast cancer based on bone scans. In addition, we analyzed radiation-associated SRFs and identified radiotherapy (RT) fa...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2020.07.009
更新日期：2020-07-23 00:00:00
abstract：BACKGROUND:Radiation therapy (RT) is often delivered after lumpectomy for women with breast cancer. A common perceived side effect of RT is fatigue, yet its exact effect on activity levels and sleep is unknown. In this study we analyzed the change in activity levels and sleep using an activity tracking device before, d...
journal_title：Clinical breast cancer
pub_type： 临床试验,杂志文章
doi：10.1016/j.clbc.2017.08.009
更新日期：2018-02-01 00:00:00
abstract：:Chyle fistula is not a well-known complication of axillary dissection in patients with breast cancer. Although rare, this complication can occur as a result of anatomic variation of the thoracic duct and its venous anastomosis. Injury to the lateral terminating branches or lymphatic trunk, leading to retrograde chyle ...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.3816/CBC.2006.n.030
更新日期：2006-06-01 00:00:00
abstract：INTRODUCTION:Unwanted clinical variation is common across the United States health care system and is particularly vexing in oncology owing to the complexity, morbidity, and high cost of the disease. Efforts to standardize care including guidelines and continuing medical education have had only limited impact. Disease-...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2018.12.010
更新日期：2019-04-01 00:00:00
abstract：:Adherence to endocrine therapy (ET) is a longstanding problem in breast cancer (BC) survivorship care, particularly among younger women. Younger patients have reported lower ET initiation rates and greater rates of early discontinuation and are considered an "at risk" group for nonadherence. For women who hope to have...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2016.12.002
更新日期：2017-06-01 00:00:00
abstract：BACKGROUND:The study aimed to evaluate the feasibility and reliability of ultrasound-guided vacuum-assisted breast biopsy (US-VABB) for sampling of microcalcifications indicative of cancer when stereotactic vacuum-assisted breast biopsy cannot be performed because of reasons such as thin breast tissue, insufficient thi...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2018.12.002
更新日期：2019-04-01 00:00:00
abstract：BACKGROUND:Implant-based breast reconstruction after nipple-sparing mastectomy has been the most common breast reconstruction procedure performed, for both breast cancer treatment and prophylactically. Subpectoral implant placement with partial detachment of the pectoralis major muscle has been the procedure of choice ...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2018.12.015
更新日期：2019-04-01 00:00:00
abstract：BACKGROUND:Ectopic breast tissue, which includes both supernumerary breast and aberrant breast tissue, is the most common congenital breast abnormality. Ectopic breast cancers are rare neoplasms that occur in 0.3% to 0.6% of all cases of breast cancer. PATIENTS AND METHODS:We retrospectively report, using a large seri...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2016.03.004
更新日期：2016-08-01 00:00:00
abstract：INTRODUCTION:Ensuring guideline-concordant cancer care is a Department of Veterans Affairs (VA) priority, especially as the number of breast cancer patients at VA medical centers (VAMCs) grows. We assessed the utilization and clinical impact of the 21-gene Recurrence Score test, which predicts 10-year risk of breast ca...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2017.11.018
更新日期：2018-04-01 00:00:00
